Sales of Biohaven's migraine tablet exceed expectations

Biohaven's tablet for preventive and acute treatment of episodic migraines has surpassed market expectations for the second quarter.
Photo: Kåre Viemose
Photo: Kåre Viemose

After Biohaven's migraine drug Nurtec ODT was approved for preventative treatment of episodic migraines in addition to its previous approval as an acute treatment, sales have exploded.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading